Suppliers / Wuhan Wuyao Pharmaceutical

Wuhan Wuyao Pharmaceutical

China Updated 9 July 2026

Wuhan Wuyao Pharmaceutical is an API manufacturer based in China. It holds 12 valid CEPs across a filed portfolio of 11 molecules. Its GMP standing is certified by US FDA and EMA. Its most recent recorded inspection, by US FDA, closed on 7 March 2025 as VAI.

0
active US DMFs
12
valid CEPs
3
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
3 of 3 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 7 March 2025 VAI US FDA
  • 9 March 2018 NAI US FDA
  • 13 May 2016 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Huangshi City, China Not on file
Huangshi, China Not on file
China, China 3010686159

What they file, and where

Molecule Regulators Docs
Norepinephrine EDQM, SFDA (Saudi Arabia) 3
Epinephrine EDQM 2
Metronidazole EDQM 2
Dopamine EDQM 1
Hydroxychloroquine EDQM 1
Isoprenaline EDQM 1
Metamizole EDQM 1
Norepinephrine Bitartrate SFDA (Saudi Arabia) 1
Phenylephrine EDQM 1
Trimetazidine Dihydrochloride EDQM 1
Show all 11 molecules on file
Xylometazoline EDQM 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA None 1
EMA None 1

Questions about Wuhan Wuyao Pharmaceutical

Does Wuhan Wuyao Pharmaceutical hold a US DMF or a CEP?
Wuhan Wuyao Pharmaceutical holds 12 valid CEPs. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
Is Wuhan Wuyao Pharmaceutical FDA-registered?
One site operated by Wuhan Wuyao Pharmaceutical carries an FDA establishment identifier (FEI), which means it is registered with the FDA as a drug establishment. Registration is not the same as approval or inspection clearance.
How did Wuhan Wuyao Pharmaceutical's last inspection go?
The most recent inspection on record closed on 7 March 2025 as VAI (Voluntary Action Indicated: issues were found but did not warrant regulatory action). 3 inspections are on file.
Where does Wuhan Wuyao Pharmaceutical manufacture?
3 registered sites are on record, in China (Huangshi City, Huangshi and China). Every site is listed on this page with the register it came from.
What does Wuhan Wuyao Pharmaceutical make?
11 molecules are on record against Wuhan Wuyao Pharmaceutical, including Norepinephrine, Epinephrine, Metronidazole and Dopamine. Each links through to that molecule's full manufacturer list.
Which regulators recognise Wuhan Wuyao Pharmaceutical's GMP?
Current GMP certificates are on record from US FDA and EMA. GMP recognition covers the manufacturing site, separately from any filing on the substance itself.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Wuhan Wuyao Pharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 7 March 2025.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates